Skip to main content
Go to homepage

Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma (ANBL1232)

Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma

Description:

For complete study information, please view the study on clinicaltrials.gov

Interested in participating?
We are currently recruiting
Full IRB Study Title:
ANBL1232: Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-high-risk Neuroblastoma
IRB Study ID:
1021250-1
If you are interested in this study or have questions about your child's eligibility, please contact:
Rebecca D. Considine Research Institute, 330-543-3193 or email research@akronchildrens.org
Lead Investigator
Steven Kuerbitz, MD

Director, Divisional Research and Stem Cell Transplantation; Pediatric Hematologist-Oncologist
Showers Family Center for Childhood Cancer and Blood DisordersPediatric Stem Cell Transplant Program